Despite Soaring Revenues, Cronos Group Inc. (TSX:CRON) Is Best Avoided

Cronos Group Inc. (TSX:CRON) (NASDAQ:CRON) recently released disappointing financial results. Here is why the pot company isn’t worth the trouble.

| More on:

Cronos Group Inc. (TSX:CRON) (NASDAQ:CRON) was widely regarded as one of the pot stocks with the most upsides at the beginning of the year. Until mid-March, the firm’s share price grew by as much as 100%.

However, things began to unravel when Cronos released its less than impressive fourth-quarter earnings report. Cronos hoped to gain investors’ trust back with its Q1 2019 results, but it was largely a continuation of what we observed in its previous earnings report.

Revenues jump again

In a common theme within the marijuana industry (especially since the legalization of recreational weed in Canada), Cronos managed to improve its revenues again. The company reported revenues of $6.5 million (beating the consensus analyst estimates), up 120% year over year, and up 15% from the previous quarter.

Cronos seems to be making some headway in the high-margin cannabis oil market, which represented 23% of the company’s revenues compared to only 9% in Q1 2018. Many pot companies are desperately searching for ways to enter higher-margin segments, a much better opportunity than the dried cannabis markets. Thus, this is a positive thing to note about Cronos’ core operations.

Cronos records a net profit, but with a huge asterisk

Few people expected Cronos to record a profit, but that is exactly what the company managed to do. Cronos recorded a net income in the amount of $427.7 million. However, this figure is wildly misleading.

The Toronto-based firm benefited from the fact that its share value has declined recently, which means Cronos earned an unrealized gain on the warrants issued to Altria (which are valued based on Cronos’ share price). That’s hardly the type of profit most investors want to see.

More mixed news

There are definitely some encouraging signs in Cronos’ latest financial results. First, the company is still in the process of increasing its production capacity, which should drive revenue growth in the future. Cronos can currently produce in excess of 40,000 kilograms of marijuana per year, but the company’s peak production capacity estimates are almost three times higher than that.

Second, let’s not forget that Cronos is in possession of a lot of cash thanks to its partnership with Altria, which means that there is no need for the pot company to rely on dilutive forms of financing to fund growth operations.

However, Cronos’ operating costs increased once again, representing 214% of sales, an increase of about 75% year over year. It will therefore be critical for Cronos to find ways to cut operating costs if the firm wants to be one of the leaders in its industry.

Investor takeaway

So far this year, Cronos hasn’t justified the trust investors put in its stock. Though Cronos’ share value defied gravity for the first three months of the year, the company has been brought back to earth largely due to its lackluster financial performance. Some might wonder whether now is a good time to buy the dip, but until Cronos shows tangible improvement, I think it’s best to stay away.

Should you invest $1,000 in Aurora Cannabis right now?

Before you buy stock in Aurora Cannabis, consider this:

The Motley Fool Stock Advisor Canada analyst team just identified what they believe are the Top Stocks for 2025 and Beyond for investors to buy now… and Aurora Cannabis wasn’t one of them. The Top Stocks that made the cut could potentially produce monster returns in the coming years.

Consider MercadoLibre, which we first recommended on January 8, 2014 ... if you invested $1,000 in the “eBay of Latin America” at the time of our recommendation, you’d have $21,345.77!*

Stock Advisor Canada provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month – one from Canada and one from the U.S. The Stock Advisor Canada service has outperformed the return of S&P/TSX Composite Index by 24 percentage points since 2013*.

See the Top Stocks * Returns as of 4/21/25

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Prosper Bakiny has no position in any of the stocks mentioned. 

Confidently Navigate Market Volatility: Claim Your Free Report!

Feeling uneasy about the ups and downs of the stock market lately? You’re not alone. At The Motley Fool Canada, we get it — and we’re here to help. We’ve crafted an essential guide designed to help you through these uncertain times: "5-Step Checklist: How to Prepare Your Portfolio for Volatility."

Don't miss out on this opportunity for peace of mind. Just click below to learn how to receive your complimentary report today!

Get Our Free Report Today

More on Cannabis Stocks

Cannabis business and marijuana industry concept as the shadow of a dollar sign on a group of leaves
Stocks for Beginners

Buy the Dip Before It’s Too Late: This Canadian Stock Won’t Stay Cheap Forever

Investors might think that cannabis stocks are out, but this one could be the top Canadian stock to consider.

Read more »

a person watches a downward arrow crash through the floor
Stocks for Beginners

Plummet Alert: Is This TSX Growth Stock a Bargain or a Falling Knife?

This growth stock was once a major winner, but can investors wait for more?

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

What to Know About Canadian Cannabis Stocks for 2025

Let's dive into two top Canadian cannabis stocks and where they may be headed from here (given the recent moves…

Read more »

Researcher works in hemp field
Cannabis Stocks

Aurora Cannabis Stock Is up 46% in 2025: Are Investors Going From 5 Years of Pain to a 2025 Gain?

Shares of Aurora Cannabis have staged a comeback in 2025, outpacing the broader markets comfortably. Is ACB stock a good…

Read more »

A plant grows from coins.
Stocks for Beginners

3 Growth Stocks That Could Skyrocket in 2025 and Beyond

It could be a big year for these sectors, and these growth stocks in particular throughout 2025.

Read more »

money goes up and down in balance
Tech Stocks

2 TSX Stocks to Buy and 2 to Avoid in the Looming Trade War

The looming U.S.-Canada trade war has changed the business environment. Here are some TSX stocks to buy and avoid in…

Read more »

space ship model takes off
Cannabis Stocks

2 Canadian Stocks With Strong Momentum for 2025

Celestica Inc. (TSX:CLS) stock and Dollarama (TSX:DOL) stock have sustained strong price growth momentum for a long time.  Here’s why…

Read more »

Worker tags plants at an industrial cannabis operation
Cannabis Stocks

Pot Stocks: Buy, Sell, or Hold in 2025?

Cannabis stocks remain a bit risky, but could long-term investors be in for more pain or far more profits?

Read more »